Advantage Alpha Capital Partners LP Harvard Bioscience Inc Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 23,617 shares of HBIO stock, worth $51,248. This represents 0.02% of its overall portfolio holdings.
Number of Shares
23,617Holding current value
$51,248% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding HBIO
# of Institutions
96Shares Held
31.5MCall Options Held
700Put Options Held
2.1K-
Black Rock Inc. New York, NY2.84MShares$6.17 Million0.0% of portfolio
-
Punch & Associates Investment Management, Inc. Edina, MN2.77MShares$6.02 Million0.44% of portfolio
-
Harvey Partners, LLC Tarrytown, NY2.72MShares$5.89 Million0.87% of portfolio
-
Amh Equity LTD2.39MShares$5.18 Million8.88% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$4.67 Million0.0% of portfolio
About HARVARD BIOSCIENCE INC
- Ticker HBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 41,636,500
- Market Cap $90.4M
- Description
- Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...